Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028
When Amgen bought marketing rights to psoriasis pill Otezla for $13.4 billion two years ago, the company was likely counting on not having to compete against early ge...
Continue Reading →
